Jamieson is pleased to announce its role advising Group CEO Mario Gualano and the management of BBI Group on the sale of the business to global life sciences investor Novo Holdings A/S.
Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests.
BBI is headquartered in South Wales and has over 400 employees across its sites in seven countries and four continents.
Stuart Coventry, Gus Gayford and Fionn Dillon Kelly advised the BBI team on their reinvestment into the new structure alongside Novo and the terms of the management incentive plan going forwards.
